Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank - Wikidata - awgldk - TriplyDB

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

http://www.wikidata.org/entity/Q33452129

about

Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.Determination of alpha-1 antitrypsin level in patients with severe asthma.A review of augmentation therapy for alpha-1 antitrypsin deficiency.Reference and interpretive ranges for α(1)-antitrypsin quantitation by phenotype in adult and pediatric populations.Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent.The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB.Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.α1-Antitrypsin deficiency.Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

P2860

Q33649874-819B35C6-7CA0-4284-8307-1547CE32CF34 Q34126916-B5D4410C-FBD0-44B5-BAEE-D9CCEC9D07C6 Q34268108-3B9F2A1F-B08F-4DE9-9BB5-9633F2AD00BE Q34295276-FE92A11D-BE66-4F8C-931A-13407E8E2EE0 Q34938414-DF73ED8E-5CFE-4235-88FA-507BC7556136 Q35063726-BBE87E1C-7A91-4B89-BEE3-44A922173398 Q35233352-B52E2D9B-BF9D-49DD-A363-A7DB480B6C96 Q36490121-79FBC73E-4161-4013-B6BE-3B9108B747E7 Q37774788-A30EE87F-90B1-4245-9B45-8EDE8ADCD644 Q37986292-BE60CAD4-2587-4724-B544-E82FC6836919 Q38604630-C6D56628-35CC-43A7-B50E-09F328C0E414 Q38988633-DE098BD0-265C-4D6F-AB35-25334F63FE23 Q41138327-3AC585FD-7FB3-4455-8607-B4F8D90900EF Q42924805-0F799DA1-7707-480C-A74F-C53D00E4EA8E Q46183542-C17672C3-9866-4E02-9553-CD5278072B08 Q49437744-B2A763F6-A027-49B1-91AE-901820D2ECBD Q51481224-399484AE-2631-4A67-8525-BCBE27B74DC6 Q55666746-9A78AEC5-A846-4120-B082-DC01364E24A1

P2860

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank

http://www.wikidata.org/entity/Q33452129

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@ast

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@en

type

label

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@ast

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@en

prefLabel

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@ast

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@en

P1433

Q33452129-B2A93D68-3B2F-4373-85D6-F1D3C288ED5E

P1476

Q33452129-A185F653-F8B4-41E7-B6F2-477652E719D6

P2093

Q33452129-106FD3CD-474C-4B70-B363-131F0151DBE2

Q33452129-8D11D85F-F28F-4BEA-B161-F26FDB63BE08

Q33452129-9D7E2532-F7EC-46C1-BDB3-2CEA5F022DC9

Q33452129-D34597C7-A22F-4B05-A971-FFBD7DE57C3B

P2860

Q33452129-23BCF6AE-A332-4B37-B2E5-378113E1E586

Q33452129-3606D628-BD50-4E59-ACCD-9FCC02FC76F2

Q33452129-392422A8-27AE-4062-AEE2-BE48253E1D9C

Q33452129-3CA1B0B8-E6FE-4D9D-A72B-1F527CEF6481

Q33452129-3FA716F9-6CF4-4F9F-8643-C7F61409A2A6

Q33452129-42F4BA8D-CDE0-462E-BAAF-031779230523

Q33452129-45A90CED-F48C-48F7-9EF8-494E2581B5B1

Q33452129-876AF308-EF62-410E-AF93-1147F86ED1C0

Q33452129-9FFF287F-079F-4F89-B580-5CB1E0E213A9

Q33452129-A719CA84-E833-438F-B551-10201F256B96

P304

Q33452129-D5AF1831-56CA-4888-A8B9-A8779543AA17

P31

Q33452129-991451D1-2AF1-4677-987E-869AF15AC092

P356

Q33452129-588EA0DC-5DD4-4D08-BBD9-895AF23C7C06

P407

Q33452129-BA05A845-802D-4DCA-AD66-D01DF0DF639A

P478

Q33452129-CF3E5712-2AC5-4307-B6AA-B786CE3B110C

P50

Q33452129-AB833894-B160-4385-8DC6-C2E6E16BE491

P577

Q33452129-852E11D6-1675-4CD2-83E7-78E7E656892D

P698

Q33452129-D608D427-DF96-4B4F-AAD1-FF9478548963

P932

Q33452129-B8308FA7-41C9-48C4-B063-ADAD4D8FEB12

P356

P1433

International Journal of Chronic Obstructive Pulmonary Disease

P1476

Alpha-1-antitrypsin augmentati ...... Foundation DNA and Tissue Bank

@en

P2093

Farshid Rouhani

http://www.w3.org/2001/XMLSchema#string

Mark L Brantly

http://www.w3.org/2001/XMLSchema#string

Ning Li

http://www.w3.org/2001/XMLSchema#string

Pam Schreck

http://www.w3.org/2001/XMLSchema#string

P2860

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.

Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ)

Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).

Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema

Molecular basis of alpha-1-antitrypsin deficiency.

The pathogenesis of chronic obstructive lung diseases: implications for therapy.

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes.

Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.

Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.

P304

443-452

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/COPD.S8577

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Adriano R. Tonelli

P577

2009-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20054436

http://www.w3.org/2001/XMLSchema#string

P932

2802045

http://www.w3.org/2001/XMLSchema#string